Appendix 4E
Preliminary final report

Rule 4.3A
Introduced 1/1/2003

Name of Entity: Chrysos Corporation Limited
ABN: 76 613 131 141

1. Reporting period ("current period"): Year ended 30 June 2026
   Previous corresponding period: Year ended 30 June 2025

2. Results for announcement to the market:

				$A'000
Revenue	up	33%	to	88,110
Profit / (loss) from ordinary activities after tax attributable to shareholders	up	122%	to	1,790
Net profit / (loss) for the period attributable to shareholders	up	122%	to	1,790

Dividends	Amount per share cents	Franked amount per share cents
Final	-	-
Interim	-	-

Record date for determining entitlements to dividends: N/A

Brief explanation of figures above (if necessary):
N/A

3. Condensed consolidated income statement

	Current Period $A'000	Previous corresponding period $A'000
PhotonAssay™ revenue	87,999	65,990
Revenue from consumables	111	122
Other income	1,057	1,210
PhotonAssay™ expenses	(21,264)	(15,672)
Employee benefit expenses	(27,310)	(23,624)
Consulting and advisory fees	(994)	(1,273)
Consumables cost of sales	(52)	(18)
Travel and marketing costs	(2,690)	(2,484)
IT costs	(3,190)	(2,380)
Other expenses	(5,528)	(4,528)
Impairment expenses	(906)	-
Depreciation and amortisation expense	(21,386)	(15,261)
Finance costs	(7,643)	(4,962)
Profit / (loss) before income tax	**(1,796)**	**(2,880)**
Income tax benefit/(expense)	3,586	(5,343)
Profit / (loss) for the year	**1,790**	**(8,223)**
Other comprehensive income for the year		
Items that may be reclassified subsequently to profit or loss		
Exchange differences arising on translation of foreign operations	(5,421)	4,268
Total comprehensive loss for the year attributable to the owners from continuing operations	**(3,631)**	**(3,955)**
Revenue & other Income		
PhotonAssay™ Revenue		
PhotonAssay™ revenue – minimum lease payments	62,487	55,892
PhotonAssay™ revenue – variable lease payments	25,512	10,098
	87,999	**65,990**
Revenue from consumables	111	122
Other Income		
Insurance recovery	886	-
Interest	171	1,210
	1,057	**1,210**

Expenses:

Loss before income tax includes the following specific expenses:		
Depreciation		
Property, plant and equipment	1,086	944
Deployed units	18,580	13,049
Total depreciation	**19,666**	**13,993**
Amortisation		
Intellectual property	405	355
Right-of-use assets	1,315	913
Total amortisation	**1,720**	**1,268**
Total Depreciation and Amortisation	**21,386**	**15,261**
Finance costs		
Interest and finance charges paid/payable on other liabilities	5,059	2,732
(Gains)/Losses on foreign exchange	2,882	2,135
(Gains)/Losses on forward exchange contract	(298)	95
Finance costs expensed	**7,643**	**4,962**
Contributions to defined contribution plans	2,789	2,211

4. Condensed consolidated balance sheet

	Current Period $A'000	Previous corresponding period $A'000
Current assets		
Cash and cash equivalents	25,892	21,520
Trade and other receivables	33,123	27,119
Research and development receivable	-	588
Other current assets	6,500	3,717
Prepayments	12,799	11,206
Total current assets	**78,314**	**64,150**
Non-current assets		
Property, plant and equipment	204,188	186,115
Right-of-use assets	3,776	4,411
Intangible assets	8,027	6,391
Other financial assets	385	100
Deferred tax asset	11,781	3,143
Total non-current assets	**228,157**	**200,160**
Total assets	**306,471**	**264,310**
Current liabilities		
Trade and other payables	34,723	34,033
Lease liabilities	839	990
Employee benefits	6,371	5,705
Other financial liabilities	246	308
Provisions	-	49
Loans and borrowings	-	2,277
Total current liabilities	**42,179**	**43,362**
Non-current liabilities		
Lease liabilities	4,047	4,463
Employee benefits	676	500
Other financial liabilities	1,918	2,546
Loans and borrowings	59,445	15,137
Deferred tax liabilities	528	-
Total non-current liabilities	**66,614**	**22,646**
Total liabilities	**108,793**	**66,008**
Net assets	**197,678**	**198,302**
Equity		
Issued capital	215,370	214,261
Accumulated losses	(18,684)	(21,945)
Reserves	992	5,986
Total equity	**197,678**	**198,302**

5. Condensed consolidated statement of cash flows

	Current Period $A'000	Previous corresponding period $A'000
Net Cash flows from operating activities		
Receipts from customers (inclusive of GST)	93,886	65,992
Payments to suppliers and employees (inclusive of GST)	(70,953)	(54,366)
Interest income	171	1,210
Interest paid	-	(701)
Income tax paid	(5,175)	(3,303)
Net cash from operating activities	**17,929**	**8,832**
Cash flows from investing activities		
Payments for intangibles	(2,041)	(2,568)
Payments for property, plant and equipment	(38,970)	(66,154)
Net cash used in investing activities	**(41,011)**	**(68,722)**
Cash flows from financing activities		
Proceeds from issue of share capital	855	2,607
Transaction costs of issue of share capital	(17)	(18)
Proceeds from loan borrowings	100,123	18,146
Proceeds from lease incentives	-	440
Payment of derivative premium	(76)	(100)
Repayment of lease liabilities	(1,689)	(1,182)
Interest paid	(4,382)	(1,884)
Repayment of borrowings	(57,537)	(732)
Transaction costs related to loans and borrowings	(1,048)	-
Net cash from financing activities	**36,229**	**17,277**
Net increase / (decrease) in cash & cash equivalents	**13,147**	**(42,613)**
Cash & cash equivalents at the beginning of the financial period	**21,520**	**61,067**
Effects of exchange rate changes on the balance of cash & cash equivalents in foreign currencies	(8,775)	3,066
Cash & cash equivalents at the end of the financial period	**25,892**	**21,520**

6. Dividends

		Amount per security	Franked amount per security at 30% tax	Amount per security of foreign source dividend
		Cents	Cents	Cents
Final Dividend	Current year	-	-	-
	Previous year	-	-	-
Interim Dividend	Current year	-	-	-
	Previous year	-	-	-

All securities for the year	Current period	Previous corresponding period
Ordinary securities	116,501,297	116,311,297
Preference securities	-	-
Other equity instruments	-	-
Total	116,501,297	116,311,297

7. Dividend reinvestment plans

The dividend reinvestment plans shown below are in operation:
None

Last date for receipt of election notices for the dividend reinvestment plan: N/A

8. Retained Earnings

	Current period $'000	Previous corresponding period $'000
Accumulated Losses at beginning of financial period	(21,945)	(14,788)
Net profit / (loss) attributable to members	1,790	(8,223)
Performance rights lapsed and moved to retained earnings	1,471	1,066
Accumulated Losses at end of financial period	(18,684)	(21,945)

9. Net Tangible Assets

Net Tangible Assets excludes intangibles and deferred tax assets, and includes right-of-use assets.

	Current period $	Previous corresponding period $
Net tangible asset backing per ordinary share	1.53	1.62

10. Details of entities which control has been gained or lost

Chrysos Corporation Limited has the following 100% wholly owned subsidiaries which were incorporated during the financial period:

- PhotonAssay Ethiopia Pty Ltd (Incorporated in Australia on 23 October 2025)
- PhotonAssay Finland Pty Ltd (Incorporated in Australia on 16 March 2026)
- PhotonAssay Morocco Pty Ltd (Incorporated in Australia on 13 March 2026)
- PhotonAssay Peru Pty Ltd (Incorporated in Australia on 13 March 2026)
- PhotonAssay Suriname Pty Ltd (Incorporated in Australia on 23 October 2025)
- PhotonAssay Chile SpA (Incorporated in Chile on 17 November 2025)
- Chrysos PhotonAssay Ghana Ltd (Incorporated in Ghana on 1 July 2025)

Chrysos Operations Ltd, an entity incorporated in Tanzania, and previously disclosed in the Group's CEDS statement as tax resident in Tanzania, was deregistered during the year.

11. Details of associates and joint venture entities

N/A

12. Any other significant information

N/A

13. Accounting Standards

The financial report is a general-purpose financial report that has been prepared in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) other authoritative pronouncements of the Australian Accounting Standards board and the Corporations Act 2001.

14. Results for the period

14.1. Earnings per security

	Current period Cents	**Previous corresponding period Cents**
Basic earnings / (loss) per share	1.54	(7.13)
Diluted earnings / (loss) per share	1.52	(7.13)

	Current period Number	**Previous corresponding period Number**
Weighted average number of ordinary shares outstanding during the period used in the calculation of basic earnings / (loss) per share	116,444,745	115,316,341
Weighted average number of ordinary shares outstanding during the period used in the calculation of diluted earnings / (loss) per share	117,717,507	115,316,341

14.2. Returns to shareholders

N/A

14.3. Significant features of operating performances

Continued growth due to deployment of PhotonAssay™ Max Units.

14.4. Segment Results

	Current period $'000	Previous corresponding period $'000
Segment revenues		
APAC	39,936	22,896
EMEA	25,800	24,917
Americas	23,358	18,299
Corporate and elimination	(984)	-
Total segment revenues	**88,110**	**66,112**
Unallocated other income	1,057	1,210
Total revenue and other income	**89,167**	**67,322**
PhotonAssay™ expenses		
APAC	(7,432)	(6,648)
EMEA	(7,807)	(3,665)
Americas	(6,025)	(5,359)
Total PhotonAssay™ expenses	**(21,264)**	**(15,672)**
Segment depreciation & amortisation		
APAC	(7,372)	(5,536)
EMEA	(5,377)	(5,166)
Americas	(5,831)	(3,075)
Total of segment depreciation & amortisation	**(18,580)**	**(13,777)**
Other segment expenses	(131)	(18)
Total segment expenses	**(39,975)**	**(29,467)**
Segment results: Profit before tax		
APAC	25,132	10,709
EMEA	12,500	16,071
Americas	11,487	9,865
Corporate and elimination	(984)	-
Total of segments	**48,135**	**36,645**
Reconciliation of reportable segment to profit / (loss) before tax		
Segment profit	48,135	36,645
Unallocated central costs	(49,931)	(39,525)
Profit / (Loss) before tax	**(1,796)**	**(2,880)**
Income tax benefit / (expense)	3,586	(5,343)
Profit / (loss) for the period	**1,790**	**(8,223)**
Segment Capital Expenditure		
APAC	14,834	15,438
EMEA	-	8,532
Americas	16,206	19,751

	Assets		Liabilities	
	Current period $'000	**Previous corresponding period $'000**	**Current period $'000**	**Previous corresponding period $'000**
APAC – Current	10,234	4,772	-	219
APAC – Total	57,416	44,924	300	1,349
EMEA – Current	10,809	9,745	230	-
EMEA – Total	42,810	49,848	1,132	531
Americas – Current	7,312	5,456	16	-
Americas – Total	55,312	45,724	732	884
Total of Segments	**155,538**	**140,496**	**2,164**	**2,764**
Unallocated assets	150,933	123,814	106,629	63,244
Total	**306,471**	**264,310**	**108,793**	**66,008**

14.5. Trends in performance

Both revenue and EBITDA are within the guidance range.

14.6. Other factors affecting current and future results

N/A

15. This report is based on accounts to which one of the following applies

✓ The accounts have been audited
o The accounts have been subject to review
o The accounts are in the process of being audited or subject to review
o The accounts have not been audited or reviewed

16. Description of any likely audit dispute or qualification

N/A

Sign here:

Company Director
Dirk Moore Treasure

Date: 10 August 2026